The Present Status in All-trans Retinoic Acid (ATRA) Treatment for Acute Promyelocytic Leukemia Patients: Further Understanding and Comprehensive Strategy are Required in the Future

References

• Huang M. E., Ye Y. C., Chai J. R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567, 572.
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., et al. All trans retinoic acid as a differentiation therapy for acute promyeloctyic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrel R. P., Jr, Frankel S. R., Miller W. H., Jr. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New England Journal of Medicine 1991; 324: 1385–1393, et al.(.
   PubMed Web of Science ®Google Scholar
• Chen Z. X., Xue Y. Q., Zhang R., et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Fenaux P, Degos L. Editorial: Treatment of acute promyelocytic leukemia with all-trans retinoic acid. Leukemia Research 1991; 15: 655–657
   PubMed Web of Science ®Google Scholar
• Frankel S. R., Eardley A., Lauwers G., Warrel R. P., Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. 1992, submitted).
   Google Scholar
• Muindi J., Frankel S. R., Miller W. H., Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinbid “resistance” in patients with acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Muindi J., Frankel S. R., Huselton C., et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Research 1992; 52: 2138–2142
   PubMed Web of Science ®Google Scholar
• Boylan J. F., Gudas L. J. Overexpression of the cellular retinoic acid binding protein-1 (CRABP-1) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells. Journal of' Cell Biology 1991; 112: 965–979
   PubMed Web of Science ®Google Scholar
• Cornic M., Delva L., Balitrand N., et al. Characterization of cytoplasmic retinoic acid binding protein (CRABP) during therapy of RA in promyelocytic acute leukemia. Proc. Am. Assoc. Cancer 1991; 32: 23
   Google Scholar
• Sun G. L., Huang M. E., Chen S. R., et al. The study on post-induction remission therapies in complete remission patients with APL induced by all-trans retinoic acid. Chinese Journal of Hematology 1990; 11: 402
   Google Scholar
• Alcalay M., Zangilli D., Pandolfi P. P., et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc. Natl. Acad. Sci. USA 1991; 88: 1977–1981
   PubMed Web of Science ®Google Scholar
• De The H., Lavau C., Marchio A., et al. The PML-RAR fusion mRNA generated by the t[15; 171 translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675–684
   PubMed Web of Science ®Google Scholar
• Biondi A., Rambaldi A., Alcalay M., et al. RAR gene rearrangement as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. Blood 1991; 77: 1418–1422
   PubMed Web of Science ®Google Scholar
• Coco F. L., Avvisati G., Diverio D., et al. Molecular evaluation of response to all-trans retinoic acid therapy in patients with acute promeylocytic leukemia. Blood 1991; 77: 1657–1659
   PubMed Web of Science ®Google Scholar
• Longo L., Pandolfi P. P., Biondi A., et al. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic Leukemia. Journal of Experimental Medicine 1990; 172: 1511–1575
   Web of Science ®Google Scholar
• Chen Z., Chen S. J., Tong J. H., et al. The retinoic acid alpha receptor gene is frequently disrupted in its 5′ part in Chinese patients with acute promyelocytic leukemia. Leukemia 1991; 5: 288
   PubMed Web of Science ®Google Scholar
• Chang K. S., Lu J. F., Wang G., et al. The t[15;17] breakpoint in acute promyelocytic leukemia cluster within two different sites of MYL gene: Targets for the detection of minimal residual disease by the polymerase chain reaction. Blood 1992; 19: 554–558
   Google Scholar
• Miller W. H., Jr, Kakizuka A., Frankel S. R., El Al. Reverse transcription polumerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 1992; 89: 2694–2698
   PubMed Web of Science ®Google Scholar
• Michaeli J., Lebedev Y. B., Richon V. M., et al. Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells. Molecular and Cellular Biology 1990; 10: 3535–3540
   PubMed Web of Science ®Google Scholar
• Richon V. M., Weich N., Leng L., et al. Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation. Proc. Natl. Acad Sci. USA 1991; 88: 1666–1670
   PubMed Web of Science ®Google Scholar
• Breitman T. R., He Ruyi. Combination of retinoic acid with either sodium bytyrate, dimethyl sulfoxide or hexamethylene bisacetainide synergistically induce differentiation of the human myeloid leukemia cell line HL-60. Cancer Research 1990; 50: 6268–6273
   PubMed Web of Science ®Google Scholar
• Zhou J. Y., Norman A. W., Akashi M., et al. Development of a novel1, 25(OH)2 Vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 1991; 78: 75–82
   PubMed Web of Science ®Google Scholar
• He Ruyi, Breitman T. R. Retinoic acid inhihits sodium butyrate-induced monocytic differentiation of HL-60 cells while hynergistically inducing granulocytoid differentiation. European Journal of Hematology 1991; 46: 93–100
   PubMed Web of Science ®Google Scholar
• Peck R, Bollag W. Potentiation of retinoid induced differentiation of HL-60 and U-937 cell lines by cytokines. European Journal of Cancer 1991; 27: 53–51
   PubMed Web of Science ®Google Scholar
• Santini V., Delwel R., Lowenberg B. Terminal granulocytic maturation in acute myeloid leukemia (AML) following granulocyte colony stimulating factor (G-CSF) and retinoic acid (RA) stimulation. Experiental Hematology 1989; 17: 646
   Google Scholar
• Olsson I. L., Breitman T. R., Gallo R. C. Priming of human myeloid leukemia cell line HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3′,5′-monophosphate-inducing agents and a T-lymphocyte derived differentiation factor. Cancer Research 1982; 42: 3928
   PubMed Web of Science ®Google Scholar
• Boyd A. W., Sullivan J. R. Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug harringtonine. Blood 1984; 63: 384–392
   PubMed Web of Science ®Google Scholar
• Hassan T, Rees J. K. H. Triple combination of retinoic acid plus low concentration of cytosine arabinoside plus hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. Hematological Oncology 1989; 7: 429–440
   PubMed Web of Science ®Google Scholar
• Hassan T, Rees J. Triple combination of retinoic acid plus 6-thioguanine plus hexamethylene bisacetamide induces digerentiation of human AML blast in primary culture. Leukemia Research 1990; 14: 109–117
   PubMed Web of Science ®Google Scholar